Viatris Comprehensive Income 2010-2024 | VTRS

Viatris comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
  • Viatris comprehensive income for the quarter ending September 30, 2024 was $-2.686B, a 16.28% decline year-over-year.
  • Viatris comprehensive income for 2023 was $-2.747B, a 0.5% decline from 2022.
  • Viatris comprehensive income for 2022 was $-2.761B, a 58.3% increase from 2021.
  • Viatris comprehensive income for 2021 was $-1.744B, a 103.3% increase from 2020.
Viatris Annual Comprehensive Income
(Millions of US $)
2023 $-2,747
2022 $-2,761
2021 $-1,744
2020 $-858
2019 $-1,797
2018 $-1,441
2017 $-361
2016 $-2,264
2015 $-1,764
2014 $-987
2013 $-240
2012 $-86
2011 $-88
2010 $172
2009 $12
Viatris Quarterly Comprehensive Income
(Millions of US $)
2024-09-30 $-2,686
2024-06-30 $-2,975
2024-03-31 $-2,941
2023-12-31 $-2,747
2023-09-30 $-3,209
2023-06-30 $-3,006
2023-03-31 $-2,765
2022-12-31 $-2,761
2022-09-30 $-3,759
2022-06-30 $-2,899
2022-03-31 $-2,061
2021-12-31 $-1,744
2021-09-30 $-1,472
2021-06-30 $-1,205
2021-03-31 $-1,386
2020-12-31 $-858
2020-09-30 $-1,424
2020-06-30 $-2,025
2020-03-31 $-2,454
2019-12-31 $-1,797
2019-09-30 $-2,191
2019-06-30 $-1,542
2019-03-31 $-1,711
2018-12-31 $-1,441
2018-09-30 $-1,491
2018-06-30 $-1,199
2018-03-31 $-192
2017-12-31 $-361
2017-09-30 $-611
2017-06-30 $-956
2017-03-31 $-1,813
2016-12-31 $-2,264
2016-09-30 $-1,120
2016-06-30 $-1,431
2016-03-31 $-1,291
2015-12-31 $-1,764
2015-09-30 $-1,554
2015-06-30 $-1,352
2015-03-31 $-1,611
2014-12-31 $-987
2014-09-30 $-620
2014-06-30 $-153
2014-03-31 $-159
2013-12-31 $-240
2013-09-30 $-251
2013-06-30 $-355
2013-03-31 $-208
2012-12-31 $-86
2012-09-30 $-36
2012-06-30 $-213
2012-03-31 $29
2011-12-31 $-88
2011-09-30 $44
2011-06-30 $454
2011-03-31 $338
2010-12-31 $172
2010-09-30 $124
2010-06-30 $-317
2010-03-31 $-43
2009-12-31 $12
2009-09-30 $-45
2009-06-30 $-271
2009-03-31 $-599
Sector Industry Market Cap Revenue
Medical Medical Services $15.433B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $95.766B 11.88
Cencora (COR) United States $49.023B 18.08
DiDi Global (DIDIY) China $23.330B 0.00
ICON (ICLR) Ireland $17.511B 15.60
Natera (NTRA) United States $16.712B 0.00
Avantor (AVTR) United States $14.831B 22.24
Revvity (RVTY) United States $14.647B 25.44
BioMerieux (BMXMF) France $12.894B 0.00
CochLear (CHEOY) Australia $12.739B 0.00
Solventum (SOLV) United States $12.214B 0.00
Medpace Holdings (MEDP) United States $11.215B 31.59
Charles River Laboratories (CRL) United States $11.042B 21.34
Doximity (DOCS) United States $10.778B 63.79
HealthEquity (HQY) United States $8.750B 47.49
Sonic Healthcare (SKHHY) Australia $8.450B 0.00
Bausch + Lomb (BLCO) Canada $6.881B 32.03
Life Times (LTH) United States $5.005B 33.12
Sotera Health (SHC) United States $4.402B 23.55
Organon (OGN) United States $4.012B 4.05
Surgery Partners (SGRY) United States $3.759B 42.85
BrightSpring Health Services (BTSG) United States $3.402B 72.37
PACS (PACS) United States $3.129B 0.00
Concentras Parent (CON) United States $2.579B 0.00
Alignment Healthcare (ALHC) United States $2.523B 0.00
Ardent Health Partners (ARDT) United States $2.446B 0.00
Premier (PINC) United States $2.301B 11.48
GeneDx Holdings (WGS) United States $2.113B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
GoodRx Holdings (GDRX) United States $1.783B 47.00
Teladoc Health (TDOC) United States $1.670B 0.00
Progyny (PGNY) United States $1.551B 29.62
Pediatrix Medical (MD) United States $1.331B 13.02
CareDx (CDNA) United States $1.251B 0.00
Establishment Labs Holdings (ESTA) $1.184B 0.00
AMN Healthcare Services Inc (AMN) United States $0.993B 6.72
Embecta (EMBC) United States $0.898B 5.99
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
InnovAge Holding (INNV) United States $0.778B 0.00
Agilon Health (AGL) United States $0.770B 0.00
SBC Medicals (SBC) United States $0.717B 0.00
Auna S.A (AUNA) Luxembourg $0.510B 0.00
Sonida Senior Living (SNDA) United States $0.442B 0.00
DocGo (DCGO) United States $0.426B 16.00
Enhabit (EHAB) United States $0.383B 33.09
COMPASS Pathways (CMPS) United Kingdom $0.346B 0.00
LifeMD (LFMD) United States $0.310B 0.00
ModivCare (MODV) United States $0.244B 13.24
Sera Prognostics (SERA) United States $0.242B 0.00
Beauty Health (SKIN) United States $0.211B 0.00
Nutex Health (NUTX) United States $0.204B 0.00
Biodesix (BDSX) United States $0.204B 0.00
MultiPlan (MPLN) United States $0.141B 0.00
Ascend Wellness Holdings (AAWH) United States $0.120B 0.00
So-Young (SY) China $0.073B 17.77
Singular Genomics Systems (OMIC) United States $0.057B 0.00
Harvard Apparatus Regenerative Technology (HRGN) United States $0.054B 0.00
OncoCyte (OCX) United States $0.051B 0.00
NeueHealth (NEUE) United States $0.042B 1.12
Co-Diagnostics (CODX) United States $0.037B 0.00
Pheton Holdings (PTHL) China $0.029B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.027B 0.00
IceCure Medical (ICCM) Israel $0.027B 0.00
Oncology Institute (TOI) United States $0.022B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
XWELL (XWEL) United States $0.009B 0.00
Intelligent Bio Solutions (INBS) United States $0.009B 0.00
BioNexus Gene Lab (BGLC) $0.006B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00